| News & Announcements | 07/01/2026 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | | | | | | 7/1/2026 | | | |
| Notifications | Modifiers XE, XP, XS, XU, and 59 | 03.00.08g | 7/1/2026 2:00 PM | 10/1/2026 | | | 7/1/2026 | Coverage and/or Reimbursement Position | | |
| Notifications | Bundled Procedure Codes | 00.01.52ac | 7/1/2026 2:00 PM | 10/1/2026 | | | 7/1/2026 | Coverage and/or Reimbursement Position | | |
| Notifications | Bioengineered Skin Substitutes | 11.08.20at | 7/2/2026 2:00 PM | 10/1/2026 | | | 7/2/2026 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | High-Technology Radiology Services | 09.00.46aw | | 5/17/2026 | | | 7/1/2026 | Medical Coding | | |
| Updated Policies | Ankle-Foot/Knee-Ankle-Foot Orthosis | 05.00.39w | | 7/1/2026 | | | 7/1/2026 | Coverage and/or Reimbursement Position | | |
| Updated Policies | Preventive Care Services | 00.06.02az | | 7/1/2026 | | | 7/1/2026 | Medical Necessity Criteria;Medical Coding | | |
| Updated Policies | Self-Administered Drugs and Biologics | 08.00.78ax | | 7/1/2026 | | | 7/1/2026 | Coverage and/or Reimbursement Position;Medical Coding | | |
| Updated Policies | Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension) | 08.00.90v | | 7/13/2026 | | | 7/13/2026 | Medical Necessity Criteria;Medical Coding | | |
| Updated Policies | Ado-Trastuzumab Emtansine (Kadcyla®) | 08.01.11k | | 7/13/2026 | | | 7/13/2026 | Medical Necessity Criteria;Medical Coding | | |
| Reissue Policies | Cerliponase alfa (Brineura®) | 08.01.39d | | 12/2/2024 | 7/8/2026 | | 7/8/2026 | | | |
| Reissue Policies | Spesolimab-sbzo (Spevigo®) | 08.01.97b | | 8/12/2024 | 7/8/2026 | | 7/8/2026 | | | |
| Reissue Policies | Eculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris®) for intravenous administration | 08.00.84m | | 1/1/2026 | 7/8/2026 | | 7/8/2026 | | | |
| Reissue Policies | Margetuximab-cmkb (Margenza) | 08.01.75e | | | 7/8/2026 | | 7/8/2026 | | | |
| Reissue Policies | Bronchial Valves | 11.16.09 | | 4/1/2022 | 7/8/2026 | | 7/8/2026 | | | |
| Reissue Policies | Full-Body Monoplace or Multiplace Chamber Hyperbaric Oxygen Therapy | 07.00.03q | | 4/21/2025 | 7/8/2026 | | 7/8/2026 | | | |
| Reissue Policies | Orthoptic/Pleoptic Training | 07.13.01k | | 7/15/2024 | 7/8/2026 | | 7/8/2026 | | | |
| Reissue Policies | Treatment of Varicose Veins of the Lower Extremities and Perforator Vein Incompetence | 11.02.01v | | 1/1/2026 | 7/8/2026 | | 7/8/2026 | | | |
| Reissue Policies | Collagenase clostridium histolyticum (Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo®) | 08.01.71 | | 11/30/2020 | 7/8/2026 | | 7/8/2026 | | | |
| Reissue Policies | Trilaciclib (Cosela™) | 08.01.77e | | 10/21/2024 | 7/8/2026 | | 7/8/2026 | | | |
| Reissue Policies | Insertion of Implantable Infusion Pumps | 11.15.03o | | 10/1/2024 | 7/8/2026 | | 7/8/2026 | | | |
| Reissue Policies | Enzyme Replacement Therapy for Adenosine Deaminase Severe Combined Immune Deficiency (e.g., elapegademase-lvlr [Revcovi]) | 08.01.26e | | 1/2/2026 | 7/8/2026 | | 7/8/2026 | | | |
| Coding Update | eviCore Lab Management (Independence) | 06.02.52an | | 4/1/2026 | | | 7/1/2026 | | | |
| Coding Update | Amivantamab-vmjw (Rybrevant®) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro™) | 08.01.90d | | 7/1/2026 | | | 7/1/2026 | | | |
| Coding Update | Routine/Non-routine Vaccines | 08.01.04aj | | 7/1/2026 | | | 7/1/2026 | | | |
| Coding Update | Treatments for Complex Regional Pain Syndrome (CRPS) | 08.00.57v | | 7/1/2026 | | | 7/1/2026 | | | |
| Coding Update | Transcatheter Cardiac Valve Procedures | 11.02.25k | | 7/1/2026 | | | 7/1/2026 | | | |
| Coding Update | Belantamab mafodotin-blmf (Blenrep) | 08.02.53a | | 7/1/2026 | | | 7/1/2026 | | | |
| Coding Update | Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®) | 08.01.36h | | 7/1/2026 | | | 7/1/2026 | | | |
| Coding Update | Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related Biosimilars | 08.01.32q | | 7/1/2026 | | | 7/1/2026 | | | |
| Coding Update | Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG) | 08.00.13ao | | 7/1/2026 | | | 7/1/2026 | | | |
| Coding Update | Interleukin-5 (IL-5) Antagonist (e.g., Cinqair, Exdensur) | 08.01.23k | | 7/1/2026 | | | 7/1/2026 | | | |
| Coding Update | Intravenous (IV) Iron Preparations | 08.02.29b | | 7/1/2026 | | | 7/1/2026 | | | |
| Coding Update | Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors | 08.00.74ac | | 7/1/2026 | | | 7/1/2026 | | | |
| Coding Update | Denosumab (Prolia®, Xgeva®) and related biosimilars, and Romosozumab-aqqg (Evenity®) | 08.00.94w | | 7/1/2026 | | | 7/1/2026 | | | |
| Coding Update | Ustekinumab for Intravenous Infusion | 08.00.82q | | 7/1/2026 | | | 7/1/2026 | | | |
| Coding Update | Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located Within a Facility or on a Facility Campus | 00.10.39s | | 4/1/2026 | | | 7/7/2026 | | | |
